Background
==========

Cardiac glycosides have been used in the treatment of cardiac disease for more than 200 years. In most Western countries digitoxin has been replaced by digoxin and other drugs. Digitoxin is still today the most common cardiac glycoside prescribed in Norway \[[@B1]\]. Digoxin has a shorter elimination half life and is often regarded easier to dosage than digitoxin. However, more attention is again paid to digitoxin as a valuable cardiac drug, especially for the eldery, and perhaps its use will increase in the future \[[@B2]\].

Cardiac glycosides also have well known antiproliferative effects on tumor cells \[[@B3]-[@B5]\]. Some cardiac glycosides have been evaluated in short term animal models. The conclusion from these experiments is that very high doses, probably toxic, would be needed for obtaining anticancer effects in humans \[[@B6]\]. In contrast, we have previously found that non toxic concentrations of digitoxin and digoxin inhibits growth and induce apoptosis in different human malignant cell lines, whereas highly proliferating normal cells were not affected \[[@B7]-[@B9]\]. The capability of cardiac glycosides to induce apoptosis has recently been confirmed in other studies \[[@B10],[@B11]\]. There is a great difference in susceptibility for cardiac glycosides in different species indicating that one can not extrapolate the results from animal models into humans \[[@B4]\].

In our in vitro experiments the apoptosis-inducing effect was more potent for digitoxin than for digoxin, and for digitoxin there was a dose response pattern; the higher concentration the more apoptosis. Another recent report on the anticancer effects of different cardiac glycosides on tumor cell lines also confirms that digitoxin seems more potent than digoxin \[[@B12]\].

As previous studies on cancer risk in patients on digitalis more or less exclusively concern digoxin \[[@B13]-[@B16]\] we have studied the possible anticancer effect of digitoxin in patients with cardiac disease. Thus, we wanted to examine if the strong anticancer effects detected in vitro were evident in vivo in a patient population on the drug for cardiac disease.

Material and Methods
====================

In Norway patients on digitoxin usually have their plasma concentration checked shortly after the initiation of the treatment. The basis of the study is all cardiac patients (n = 9271, 5026 women and 4245 men) who had their first digitoxin concentration measurement carried out in the period 1986--96 at the University Hospital of Trondheim. The settlement is very stable for these patients, so our figures are not influenced by that patients have had their plasma digitoxin measured in any other hospital. The digitoxin concentrations were measured by a radio-immunoassay method (Coat-A-Count Digitoxin, Diagnostic Products Corporation, Los Angeles, USA). The reference range for therapeutic plasma digitoxin concentration at our laboratory is 15--33 nmol/1 (12--25 ng/ml). The mean age for the total digitoxin population was 75.8 years (1 SD = 10.2), for men 73.3 years (1 SD = 10.3) and women 78.0 years (1 SD = 9.5). After approval of the Norwegian Data Inspectorate, the regional ethical committee and the Norwegian Health Inspectorate, the digitoxin data were linked to individual data on cancer in the population based Norwegian Cancer Registry.

To study the association between digitoxin use and cancer, three different approaches were used.

Firstly, a prospective design was chosen. All the digitoxin users with no prior cancer diagnosis formed a basis cohort from the time they have their first digitoxin plasma concentration measurement carried out. This cohort was followed for the occurrence of cancer until the subjects died or up to December 31, 1996. The expected number of cases for each type of cancer was calculated by applying the national cancer rates matched exactly on year of birth, age and sex. The standardized incidence ration (SIR) was calculated for all types of cancers having more than 30 expected cases. The 95% confidence intervals were estimated on the basis of the Poisson-distribution.

The second approach was a retrospective design based on persons who were identified in the laboratory database as digitoxin users. For each becoming digitoxin user one control person was randomly picked out from the general population. These controls were matched by birth date and gender and they should be alive at the time when the corresponding becoming digitoxin user started on digitoxin.These two groups were compared with respect to having a cancer diagnosis during the period of observation and the Odds ratio of cancer cases before start on digitoxin was used as a risk estimate. The 95 % confidence intervals were estimated on the basis of the Mantel-Haenzel chi-square estimation. As the control persons are randomly picked out from the general population matched by birthday and gender, we do not know anything about eventual drug use in the controls. Thus, some of the controls might use digitoxin and other drugs. However, the frequency of digitalis users in the general population is so low that it is not likely to corrupt our figures significantly.

The third approach was a prospective internal dose-response on the cohort on digitoxin users where the risk of cancer was studied by different levels of digitoxin plasma concentration at first measurement divided in tertiles and a Cox regression analysis was carried out. For the trend analysis the continuous values for the digitoxin variables was used.The the lowest plasma digitoxin concentration (\< 16 ng/ml) was set as reference.

Results
=======

Table [1](#T1){ref-type="table"} demonstrates a general higher cancer incidence in the population on digitoxin compared to what is expected in the general population. However, it is not clear whether the population of digitoxin users differ from the general population in cancer risk already before start on the drug. Table [2](#T2){ref-type="table"} presents the results of the second approach where we wanted to examine if the persons on digitoxin had an increased risk of cancer already before they had started to take the drug. Here the actual number of cancer cases in the population of \"becoming digitoxin users\" is compared with the number of cases in the age and sex matched control group (presented as Odds ratio (OR) for each type of cancer). Thus, more cancer cases were seen in the group to become digitoxin users (OR \> 1.00) except for melanoma and other skin cancers. Lymphoma and leukemia are presented as a single group in the tables due to the close relationship between them. In the prospective part of the study (as presented in Table [1](#T1){ref-type="table"}) for leukemia alone SIR was 1.39 (95% CI: 0.95--1.97) (31 observed versus 22.3 expected). In the comparison between becoming digitoxin users and the controls (as presented in Table [2](#T2){ref-type="table"}), the Odds ratio for leukemia was 1.95 (95% CI: 1.42--2.67). The internal dose-response analysis is shown in Table [3](#T3){ref-type="table"}. For most types of cancer we could not find any association, neither for all types of cancer combined. However, a test for trend by level of digitoxin concentration indicated a trend toward a protective effects of high digitoxin levels for the lymphoma/leukemia group (p = 0.008) and for kidney/urinary organ cancers (p = 0.05).

###### 

Observed and expected cancer cases among digitoxin users.

  **ICD-10**          **Site**               **Sex**   **Observed**   **Expected**   **SIR (95 % CI)**
  ------------------- ---------------------- --------- -------------- -------------- -------------------
  C50                 Breast                 F         57             45.7           1.25(0.95, 1.62)
  C61                 Prostate               M         108            86.7           1.25(1.03, 1.50)
  C18--21             Colo-rectal            M+F       127            98.5           1.29(1.06, 1.51)
  C32--34             Lung                   M+F       63             46.4           1.35(1.04, 1.74)
  C64,C65,C67,C68     Kidney, urinary        M+F       59             51.8           1.14(0.87, 1.47)
  C43.C44             Melanoma, other skin   M+F       61             49.7           1.23(0.94, 1.58)
  C81--C85,C88--C92   Leukemia/Lymphoma      M+F       53             37.5           1.41 (1.06, 1.85)
  C00--C97            All sites              M+F       641            502.8          1.27(1.18, 1.37)

Observed and expected cancer cases amoung digitoxin users, and standardized incidence ratio (SIR) presented for all types of cancers having more than 30 expected cases. The cancer types are divided in the groups according to ICD-10 (International Classification of Disease).Observed=cancer cases in the population on digitoxin after start on the drug,no lag time applied. Expected=expected cancer cases calculated by applying the national cancer rates matched exactly on year of birth,age and sex.

###### 

Number of cancer cases among subjects that subsequently became digitoxin users.

  **ICD-10**        **Site**               **Sex**   **Digitoxin group**   **Control group**   **Odds Ratio (95% CI)**
  ----------------- ---------------------- --------- --------------------- ------------------- -------------------------
  C50               Breast                 F         275                   232                 1.19(1.11, 1.28)
  C61               Prostate               M         370                   296                 1.25(1.08, 1.45)
  C18--21           Colo-rectal            M+F       430                   325                 1.32(1.15, 1.52)
  C32--34           Lung                   M+F       163                   112                 1.46(1.15, 1.86)
  C64,C65,C67,C68   Kidney, urinary        M+F       201                   180                 1.06(0.95, 1.17)
  C43.C44           Melanoma, other skin   M+F       154                   191                 0.81 (0.66, 0.99)
  C81--C85,C88--    Leukemia/Lymphoma      M+F       198                   117                 1.69(1.35,2.11)
  C92                                                                                          
  C00--C97          All sites              M+F       2435                  2017                1.21 (1.15, 1.28)

Number of cancer cases among subjects that subsequently became digitoxin users,and among matched controls.Digitoxin group=the cancer cases among the 9271 patients constituting the database just before the start on digitoxin medication. Control group=for each subject in the digitoxin group one control was randomly picked out from the general population. These controls were matched on birthday and gender and should be alive at the time when the corresponding digitoxin user started on digitoxin.

Discussion
==========

The intention with the present study was to investigate whether use of digitoxin induces any changes in the incidence of cancer. One strength in our material is that we use plasma concentration measurements for defining the digitoxin using population. In previous studies drug use has been estimated by employing dispensing data or questionnaires about drug use \[[@B13]-[@B15]\]. These methods are less reliable than measuring plasma drug concentration, as neither completely account for variations in recall biases, complicance, nor for the existing inter-individual pharmacokinetic variability.

As mentioned earlier, digoxin and other cardiac glycosides are more commonly used in many countries and the use in the earlier studies is usually not specified to just one drug, but to the digitalis group of prescription drugs \[[@B13]-[@B15],[@B17]\]. We found a general higher incidence of cancer among the patients on digitoxin. This is in agreement with the earlier published studies \[[@B13]-[@B15],[@B17]\]. These studies have just presented figures on cancer incidence after commencement on the drug, as we have done in the prospective part of our study (Table [1](#T1){ref-type="table"}). The general higher incidence of cancer in the cardiac population on digitoxin thus prompted us to perform the analysis presented in Table [2](#T2){ref-type="table"}. These figures show that the population to become digitoxin using has an increased risk of having cancer also before starting on digitoxin medication. Thus there exist risk factors associated with both cancer and cardiovascular disease. For some types of cancer this association may be explained by food habits, smoking and other factors. Intake of food rich in antioxidants and a favorable composition of carbohydrates, fats and proteins as well as vitamines and minerals may reduce morbidity in both cardiovascular disease and cancer \[[@B18]\]. Smoking is an evident risk factor for both lung cancer and cardiovascular disease.

Surprisingly, the leukemia/lymphoma group shows the highest Odds ratio and melanoma/other skin cancers the lowest (Table [2](#T2){ref-type="table"}). Excessive exposition to sunlight shows a positive correlation with the development of skin cancer \[[@B19]\]. The lower Odds ratio (OR) for the development of skin cancer could hypothetically be explained by a different life style, as people who will develop cardiac disease and subsequent become digitoxin users may be more in house and therefore not exposed to sunlight to the same extent. However, the increased SIR value for skin cancer (Table [1](#T1){ref-type="table"}) is more difficult to explain.

The high risk of lymphoproliferative cancers before start on digitoxin is intriguing (Table [2](#T2){ref-type="table"}). Microbiological agents are associated with some types of cardiovascular disease and also for the development of cancer, but whether mutual agents exists are unclear \[[@B20],[@B21]\]. Our ratios are well in agreement with a previous study focusing on drug use and other factors preceding non Hodgkin lymphoma \[[@B15]\]. This substantiates that yet unknown common risk factors exist for the development of cardiovascular disease and lymphoproliferative cancer. A possible protective effect of digitoxin here is indicated by a dose response pattern in the internal analysis. In addition, human leukemic cell lines in the form of Jurkat (T-cell leukemia) and Daudi (B-cell leukemia) are among the most susceptible for apoptosis induction by digitoxin treatment in vitro \[[@B8]\]. This further support that the SIR -- OR ratio (1.39/1.95) for leukemia of 0.71 may indicate an anticancer effect.

It is evident that tracking anticancer effects in a population of patients with serious cardiac disease is hampered by several confounding factors. The mean time of digitoxin use before the cancer diagnosis is just about 3 years in our material. In general studies on cancer incidence in relation to drug use may be biased by that the cancer, before detected, induces symptoms treated by the drug of study. Moreover, as patients seek medical advice for cardiac problems they are also subjected to a more careful physical examination and a tumor may therefore be detected and diagnosed soon after the start of treatment for cardiac disease, thus leading to the false impression that the drug induced the cancer. This can be avoided by introducing lag times in the analysis. However in view of the mostly unknown time course for the occurrence and initial progression of solid tumors before they become detected, the lag time applied will be arbitrary chosen. One year lag time did not have any impact on our figures indicating that this effect has not corrupted the presented results. Another potential confounding factor is the use of other cardiac drugs in the digitoxin group. Most likely, the use of drugs such as angiotensin converting enzyme (ACE) inhibitors, calcium antagonists and warfarin is higher in the digitoxin group than in the control group. The use of ACE inhibitors and warfarin have been associated with a decreased risk of cancer \[[@B22],[@B23]\], whereas the use of calcium antagonists has been associated with an increased risk of cancer in some studies, but not in all \[[@B24]\]. Thus, use of these drugs might have affected the results in both directions. Unfortunately, information on concomitant drug use was not available in the database.

Chemotherapy, especially in the form of anthracyclines, may induce cardiac congestion and thus subsequent use of digitalis \[[@B25]\]. However, it seems that it is just a small fraction of all patients on digitalis who has had the cardiac disease as a result of chemotherapy, so this should not have corrupted our figures (Table [2](#T2){ref-type="table"}), but still it will counteract the detection of an eventual anticancer effect of digitoxin to some extent in the analysis.

Based on theoretical assumptions it may be that the cancer incidence is not dramatically changed in patients on digitalis, but that the survival nevertheless could be affected. Our material was not suited for survival analyses due the high age of the patients and the correspondingly high mortality due to cardiac disease. Cancer patients are also prone to get their cancer diagnosis on the death certificate, even if other conditions are the direct cause of death. To make a fair analysis with focus on survival time, autopsy data for most of the patients would be required \[[@B26]\], and such data were not available

###### 

An internal dose-response analysis.

  **ICD-10**   **Site**          **Digitoxin concentration ng/ml**                      
  ------------ ----------------- ----------------------------------- ------------------ -------------------
  C50          Breast            1.00 (reference)                    1.04(0.59, 1.84)   0.90(0.48, 1.67)
  C61          Prostate          1.00 (reference)                    0.79(0.51, 1.22)   0.89(0.56, 1.40)
  C18--C21     Colo-rectal       1.00 (reference)                    0.97(0.66, 1.42)   0.92(0.61, 1.40)
  C32--C34     Lung              1.00 (reference)                    1.25(0.71,2.22)    1.06(0.57,2.00)
  C64, C65     Kidney, urinary   1.00 (reference)                    0.30(0.15,0.57)    0.45 (0.24, 0.83)
  C67, C68     organs                                                                   
  C43,C44      Melanoma, other   1.00 (reference)                    1.16(0.60,2.25)    1.29(0.65,2.57)
               skin                                                                     
  C81--C85     Leukemia and      1.00 (reference)                    0.67(0.38, 1.18)   0.57(0.30, 1.08)
  C88--C92     Lymphoma                                                                 
  C00-C97      All sites         1.00 (reference)                    0.84(0.71,0.99)    0.86(0.72, 1.02)

An internal dose-response analysis. Age-adjusted relative risks (95% confidence limits) of specific types of cancer by concentration levels (tertiles) of digitoxin. A Cox regression analysis was used.

Conclusion
==========

It is evident from the present study that too many disturbing factors exist in a population with serious cardiac disease for making proper examination of possible anticancer effects of cardiac glycosides. However, our study gives some support to data from previous studies indicating a higher incidence of cancer detected in patients treated with digitalis, but this association should be ascribed to underlying factors inducing and/or promoting both cancer and cardiovascular disease and not the actual use of digitalis.

The possible role for cardiac glycosides in cancer treatment has to be evaluated in prospective clinical studies with cardiac glycosides as primary anticancer agents.
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